RLS (USA) Inc.

RLS (USA) Inc., a foreign-owned subsidiary of Telix Pharmaceuticals US Inc., supplies specialized radiopharmaceuticals and nuclear medicine diagnostic agents to the Department of Veterans Affairs and Defense Health Agency as a prime contractor on single-award indefinite delivery contracts and purchase orders, competing full-and-open with no set-aside designations across 95 federal awards totaling $73 million in combined potential value.

RLS (USA) Inc. is a for-profit radiopharmacy company headquartered in Lake Mary, Florida, operating 31 radiopharmacy facilities across 18 states. The company classifies under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals), with primary focus on time-sensitive radiopharmaceutical products including technetium-99m derivatives, gallium-67, fluorodeoxyglucose F-18, thallium-201, iodine isotopes (I-123, I-131), indium-111, Gallium-68 Dotatate (NETSPOT), and specialty agents such as locametz and Cardiolite. The company does not compete under small-business set-asides in its prime footprint, though some underlying indefinite delivery vehicles carry small-business set-aside designations at the parent level; individual delivery orders issued against those vehicles do not carry set-aside designations. RLS operates exclusively as a prime contractor with no recorded subcontract activity in the source data.

Customer concentration sits heavily with the Veterans Health Administration and Defense Health Agency. The top five customer networks by combined potential value account for 76% of all awards: Veterans Integrated Service Network 22 (8 awards, $14.1 million), VISN 17 (16 awards, $13.6 million), VISN 7 (6 awards, $10.4 million), VISN 21 (15 awards, $9.8 million), and VISN 20 (4 awards, $7.7 million). By award count, VISN 17 (16 awards), VISN 21 (15 awards), Defense Health Agency (21 awards, $6.1 million), and VISN 2 (13 awards, $1.1 million) lead. The divergence between count and dollars reflects a pattern of lower-value task orders against single-award IDIQs with larger ceilings, particularly under VISN 2's small-business set-aside NETSPOT vehicle, versus higher-value ceilings on newer VISN 22, VISN 17, and VISN 20 contracts.

RLS maintains an extensive portfolio of single-award indefinite delivery contracts and blanket purchase agreements across multiple VA networks and the Defense Health Agency. Major vehicles include a $6.99 million IDIQ with VISN 22 for Phoenix and Tucson radiopharmaceutical supply (awarded April 1, 2026), a $6 million IDIQ with VISN 20 through December 31, 2030, a $4.99 million IDIQ with VISN 17 through September 17, 2029, a $2.5 million IDIQ with VISN 21 for Northern California Health Care System through March 31, 2030, a $2.18 million IDIQ with VISN 21 for non-PET radiopharmaceuticals through March 31, 2030, a $2.16 million IDIQ with VISN 5 through March 31, 2030, a $1.9 million BPA with Defense Health Agency for Naval Medical Center San Diego through September 30, 2029, and a $538 thousand small-business set-aside IDIQ with VISN 2 for NETSPOT through July 31, 2029. Recent representative task orders include a $2.53 million purchase order from VISN 16 for radiopharmaceuticals (August 1, 2025 through May 31, 2026), a $1.71 million purchase order from VISN 12 for radiopharmaceutical and nuclear medicine products through February 28, 2031, a $1.13 million purchase order from VISN 22 for radiopharmaceuticals through November 30, 2026, and multiple smaller delivery orders under various VISN IDIQ vehicles.

Activity has remained relatively flat, averaging 16 awards per year over the past five years with a slight uptick to 23 awards in 2025 driven by a wave of new IDIQ awards in April 2025 and April 2026. Eighteen awards with combined potential value of $12 million face ultimate completion inside the next twenty-four months and represent recompete exposure, including the expiring VISN 12 IDC (completion February 28, 2025), VISN 22 purchase orders (completion through May 31, 2026), and multiple VISN 17, VISN 21, and VISN 2 delivery orders completing through December 2026. The company obligated $27.4 million across the $73 million portfolio, indicating consistent invoicing across federal healthcare customer base. RLS competes within full-and-open procurements on technical capability, past performance, and price criteria; several awards cite sole-source justifications under FAR 6.302-1 based on RLS's specialized capacity to deliver time-sensitive radiopharmaceutical products meeting Nuclear Regulatory Commission licensure, USP 797 compliance, and federal healthcare delivery requirements.

RLS is committed to maintaining high standards in the industry, from agent compounding to customer delivery. Our continuous focus on safety has created an innovative WBC labeling process that supports patient blood integrity. RLS (Radioisotope Life Sciences) sees itself as a key role player to facilitate the entry of new drugs and the installation of state of the art imaging equipment into the practice of health care. We also commit to expanding the market through alternative methods of production for Tc-99m and Ga-68. RLS maintains high-quality standards by routinely upgrading operational procedures to provide the best available practices. One of our key services is the procedure of radiolabeling autologous leukocytes (WBC labeling process). We have also implemented a uniquely keyed locking system to ensure limited access during the entire labeling process.